-
1 Comment
Shandong Sito Bio-technology Co., Ltd is currently in a long term downtrend where the price is trading 3.2% below its 200 day moving average.
From a valuation standpoint, the stock is 76.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.3.
Shandong Sito Bio-technology Co., Ltd's total revenue rose by 12.1% to $232M since the same quarter in the previous year.
Its net income has dropped by 161.0% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 113.2% to $5M since the same quarter in the previous year.
Based on the above factors, Shandong Sito Bio-technology Co., Ltd gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | CNE100002F36 |
| Market Cap | 4B |
|---|---|
| Beta | 0.05 |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 2.3% |
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. The company was founded in 2002 and is based in Heze City, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300583.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
